Mode
Text Size
Log in / Sign up

da Vinci robot-assisted surgery reduces conversion to open surgery and blood loss in oncologic proceduresRobot-Assisted Surgery Shows Better Outcomes for Certain Cancer Procedures

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that dV-RAS is associated with lower conversion rates and less blood loss, but shows no difference in operative time.

This meta-analysis synthesized data from 116 studies to evaluate the efficacy of da Vinci robot-assisted surgery (dV-RAS) compared to laparoscopic/video-assisted thoracoscopic surgery (LAP/VATS) and open surgery in patients undergoing oncologic procedures. The analysis focused on perioperative outcomes, including conversion rates, blood loss, transfusion requirements, and postoperative complications.

Key findings indicate that dV-RAS is associated with a lower odds of conversion to open surgery (OR 0.26; 95% CI 0.21-0.33; p < 0.01) and significantly less blood loss (MD -32.48 mL; 95% CI -40.86 to -24.11; p < 0.01) compared to LAP/VATS. Additionally, dV-RAS was associated with lower odds of blood transfusion (OR 0.61; 95% CI 0.51-0.73; p < 0.01), shorter hospital stays (MD -1.06 days; 95% CI -1.30 to -0.82; p < 0.01), and fewer 30-day postoperative complications (OR 0.67; 95% CI 0.61-0.73; p < 0.01). Fewer reoperations were also noted (OR 0.62; 95% CI 0.40-0.96; p = 0.03).

However, the authors noted substantial between-study heterogeneity and the fact that most included studies were retrospective. No significant differences were found between dV-RAS and other approaches regarding operative time, readmission, or 30-day mortality. These findings should be interpreted with caution due to the study quality and the reliance on retrospective data.

How this fits prior evidence

This meta-analysis addresses a gap in comparing surgical modalities for oncologic procedures. While previous evidence highlighted that nursing strategies for inflammation-sensitive care can mitigate complications in gynecologic oncology surgery, this study provides specific data on the technical advantages of dV-RAS, such as lower odds of conversion to open surgery (OR 0.26) and reduced blood loss (MD -32.48 mL) compared to LAP/VATS.

A large review of 116 studies looked at patients in China undergoing seven different types of cancer procedures. Researchers compared the use of the da Vinci robot-assisted surgery (dV-RAS) against traditional methods, such as laparoscopic, video-assisted, and open surgeries.

The review found that patients who had the robot-assisted procedure were less likely to need a conversion to open surgery. These patients also experienced less blood loss, fewer blood transfusions, and shorter hospital stays compared to those who had laparoscopic or video-assisted procedures. Additionally, there were fewer reoperations and fewer complications within 30 days after surgery.

It is important to note that these results come from a meta-analysis of mostly retrospective studies, which can limit how certain we can be about the findings. While the robot-assisted method showed several benefits, there were no significant differences in operative time, readmission rates, or 30-day mortality compared to other methods. Because of the variety in the original studies, these results should be viewed as an association rather than a guarantee of success.

What this means for you:
Robot-assisted surgery may reduce blood loss and hospital stays, but results are based on varied study types.

Common questions

What are the benefits of robot-assisted surgery for cancer?

The study found that robot-assisted surgery was associated with less blood loss, fewer blood transfusions, and shorter hospital stays compared to laparoscopic or video-assisted procedures. Patients also had a lower risk of needing to switch to open surgery and experienced fewer reoperations and complications within 30 days.

Is robot-assisted surgery faster than other methods?

The study found no significant difference in operative time between robot-assisted surgery and other surgical approaches. While it offered benefits in blood loss and recovery time, the actual time spent in the operating room was similar across the different methods studied.

Are there any risks or safety concerns with this method?

The study did not report specific adverse events or safety concerns. However, because many of the included studies were retrospective and showed high variability, these findings should be interpreted with caution. You should discuss the best surgical approach with your doctor.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
The use of robot-assisted surgery (RAS) has increased markedly in China, but comparative evidence on its perioperative performance in cancer care is dispersed across specialties and study designs. This review synthesized Chinese evidence to examine the safety and effectiveness of da Vinci robot-assisted surgery (dV-RAS) relative to laparoscopic/video-assisted thoracoscopic surgery (LAP/VATS) and open surgery across seven oncologic procedures. We systematically reviewed comparative studies published from 2010 to 2024 and pooled estimates for dV-RAS versus LAP/VATS or open surgery. Prespecified perioperative outcomes were conversion to open surgery, operative time, estimated blood loss, blood transfusion, hospital length of stay, postoperative complications, readmission, reoperation, and 30-day mortality. The review included 116 studies. Relative to LAP/VATS, dV-RAS was associated with lower odds of conversion to open surgery (odds ratio [OR] 0.26; 95% confidence interval [CI] 0.21-0.33; p < 0.01), less blood loss (mean difference [MD] - 32.48 mL; 95% CI - 40.86 to - 24.11; p < 0.01), lower odds of transfusion (OR 0.61; 95% CI 0.51-0.73; p < 0.01), a shorter hospital stay (MD - 1.06 days; 95% CI - 1.30 to - 0.82; p < 0.01), fewer 30-day postoperative complications (OR 0.67; 95% CI 0.61-0.73; p < 0.01), and fewer reoperations (OR 0.62; 95% CI 0.40-0.96; p = 0.03). Comparisons with open surgery likewise favored dV-RAS for blood loss, transfusion, length of stay, and postoperative complications. Operative time, readmission, and 30-day mortality did not differ significantly between approaches. Across seven oncologic procedures, pooled evidence from China indicated that dV-RAS was associated with better outcomes on several perioperative measures than LAP/VATS or open surgery. Because between-study heterogeneity was substantial and most included studies were retrospective, the findings should be interpreted cautiously and confirmed in higher-quality prospective research.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.